Indian IT and pharma stocks are not benefiting from a weaker rupee as expected. Tariff concerns are overshadowing currency gains. Investors are waiting for clarity on trade deals. Foreign investors have also been selling these stocks. Valuations remain a concern for pharma companies. Demand for IT services shows signs of improvement. Stock selection will be crucial for investors.
India defies West Asia war concerns as Q4 GDP growth hits 7.8%; risks remain ahead
India’s economy surged by a better-than-expected 7.8% in the March quarter, exceeding forecasts and pushing FY26 growth to 7.7%. This robust performance was driven by